1
40
4
-
Text
A resource consisting primarily of words for reading. Examples include books, letters, dissertations, poems, newspapers, articles, archives of mailing lists. Note that facsimiles or images of texts are still of the genre Text.
URL Address
<table width="91" style="border-collapse:collapse;width:68pt;"><colgroup><col width="91" style="width:68pt;" /></colgroup><tbody><tr style="height:15pt;"><td width="91" height="20" class="xl18" style="width:68pt;height:15pt;"><a href="http://doi.org/10.1021/acs.jmedchem.1c00656">http://doi.org/10.1021/acs.jmedchem.1c00656</a></td>
</tr></tbody></table>
NEOMED College
NEOMED College of Medicine
NEOMED Department
Department of Integrative Medical Sciences
Update Year & Number
Jan to Aug list 2021
Dublin Core
The Dublin Core metadata element set is common to all Omeka records, including items, files, and collections. For more information see, http://dublincore.org/documents/dces/.
Title
A name given to the resource
Lipophilic Ga Complex with Broad-Spectrum Antimicrobial Activity and the Ability to Overcome Gallium Resistance in both Pseudomonas aeruginosa and Staphylococcus aureus.
Creator
An entity primarily responsible for making the resource
Wang Z; Li J; Benin BM;Yu B; Bunge Scott D; Abeydeera N; Huang SD; Kim M-H
Publisher
An entity responsible for making the resource available
Journal Of Medicinal Chemistry
Date
A point or period of time associated with an event in the lifecycle of the resource
2021
2021-06-17
Description
An account of the resource
Antibiotic resistance (AR) necessitates the discovery of new antimicrobials with alternative mechanisms of action to those employed by conventional antibiotics. One such strategy utilizes Ga3+ to target iron metabolism, a critical process for survival. Still, Ga-based therapies are generally ineffective against Gram-positive bacteria and promote Ga resistance. In response to these drawbacks, we report a lipophilic Ga complex, [Ga2L3(bpy)2] (L = 2,2′-bis(3-hydroxy-1,4-naphthoquinone; bpy = 2,2′-bipyridine)), effective against drug-resistant Pseudomonas aeruginosa (DRPA; minimum inhibitory concentration, MIC = 10 μM = 14.8 μg/mL) and methicillin-resistant Staphylococcus aureus (MRSA, MIC = 100 μM = 148 μg/mL) without iron-limited conditions. Importantly, [Ga2L3(bpy)2] shows noticeably delayed and decreased resistance in both MRSA and DRPA, with only 8× MIC in DRPA and none in MRSA after 30 passages. This is likely due to the dual mode of action afforded by Ga (disruption of iron metabolism) and the ligand (reactive oxygen species production). Overall, [Ga2L3(bpy)2] demonstrates the utility of lipophilic metal complexes with multiple modes of action in combatting AR in Gram-positive and Gram-negative bacteria.
Subject
The topic of the resource
In recent years, drug-resistant pathogenic bacteria have spread faster than the discovery of new antibiotics. (1,2) It is estimated that more than 30% of clinical isolates of Pseudomonas aeruginosa (P. aeruginosa) from patients in any given intensive care unit or nursing home are now resistant to three or more antibiotic drugs. (3) This situation is very similar for other pathogenic organisms as well. (4) Currently, very few new antibiotics are in an advanced development stage as a result of fewer large, pharmaceutical companies engaging in antibiotic research and the fact that the successful use of soil-derived antibiotics has, after over 70 years of intensive screening, often resulted in repeated isolation of known compounds. (5) This dire situation has resulted in an increased rate of morbidity and mortality stemming from bacterial infections. (6) In the era of antibiotic resistance, a paradigm shift from the development of new antibiotics via structural modifications to nonconventional antimicrobial alternatives is warranted.
Identifier
An unambiguous reference to the resource within a given context
<table width="91" style="border-collapse:collapse;width:68pt;"><colgroup><col width="91" style="width:68pt;" /></colgroup><tbody><tr style="height:15pt;"><td width="91" height="20" class="xl18" style="width:68pt;height:15pt;"><a href="http://doi.org/10.1021/acs.jmedchem.1c00656">http://doi.org/10.1021/acs.jmedchem.1c00656</a></td>
</tr></tbody></table>
Format
The file format, physical medium, or dimensions of the resource
Journal Article
2021
Antimicrobial agents and chemotherapy
Bacteria
Gallium
ions
iron
-
Text
A resource consisting primarily of words for reading. Examples include books, letters, dissertations, poems, newspapers, articles, archives of mailing lists. Note that facsimiles or images of texts are still of the genre Text.
URL Address
<a href="http://doi.org/10.1073/pnas.0505256102" target="_blank" rel="noreferrer noopener">http://doi.org/10.1073/pnas.0505256102</a>
Rights
Article information provided for research and reference use only. All rights are retained by the journal listed under publisher and/or the creator(s).
Pages
18129-18134
Issue
50
Volume
102
Search for Full-text
Locate full-text within NEOMED Library's e-journal collections
<p>Users with a NEOMED Library login can search for full-text journal articles at the following url: <a href="https://libraryguides.neomed.edu/home">https://libraryguides.neomed.edu/home</a></p>
Dublin Core
The Dublin Core metadata element set is common to all Omeka records, including items, files, and collections. For more information see, http://dublincore.org/documents/dces/.
Title
A name given to the resource
Reduced Paneth cell alpha-defensins in ileal Crohn's disease
Publisher
An entity responsible for making the resource available
Proceedings of the National Academy of Sciences of the United States of America
Date
A point or period of time associated with an event in the lifecycle of the resource
2005
2005-12
Subject
The topic of the resource
bacteria; expression; gene; human intestinal defensin; inflammatory bowel disease; inflammatory bowel disease; innate; innate immunity; intestine; mechanisms; microflora; mutations; peptides; Science & Technology - Other Topics
Creator
An entity primarily responsible for making the resource
Wehkamp J; Salzman N H; Porter E; Nuding S; Weichenthal M; Petras R E; Shen B; Schaeffeler E; Schwab M; Linzmeier R; Feathers R W; Chu H T; Lima H; Fellermann K; Ganz T; Stange E F; Bevins C L
Description
An account of the resource
The pathogenesis of Crohn's disease (CD), an idiopathic inflammatory bowel disease, is attributed, in part, to intestinal bacteria that may initiate and perpetuate mucosal inflammation in genetically susceptible individuals. Paneth cells (PC) are the major source of antimicrobial peptides in the small intestine, including human alpha-defensins HD5 and HD6. We tested the hypothesis that reduced expression of PC alpha-defensins compromises mucosal host defenses and predisposes patients to CD of the ileum. We report that patients with CID of the ileum have reduced antibacterial activity in their intestinal mucosal extracts. These specimens also showed decreased expression of PC alpha-defensins, whereas the expression of eight other PC products either remained unchanged or increased when compared with controls. The specific decrease of alpha-defensins was independent of the degree of inflammation in the specimens and was not observed in either CD of the colon, ulcerative colitis, or pouchitis. The functional consequence of alpha-defensin expression levels was examined by using a transgenic mouse model, where we found changes in HD5 expression levels, comparable to those observed in CD, had a pronounced impact on the luminal microbiota. Thus, the specific deficiency of PC defensins that characterizes ileal CD may compromise innate immune defenses of the ileal mucosa and initiate and/or perpetuate this disease.
Identifier
An unambiguous reference to the resource within a given context
<a href="http://doi.org/10.1073/pnas.0505256102" target="_blank" rel="noreferrer noopener">10.1073/pnas.0505256102</a>
Format
The file format, physical medium, or dimensions of the resource
Journal Article
2005
Bacteria
Bevins C L
Chu H T
expression
Feathers R W
Fellermann K
Ganz T
gene
human intestinal defensin
inflammatory bowel disease
Innate
Innate immunity
Intestine
Journal Article
Lima H
Linzmeier R
mechanisms
microflora
mutations
Nuding S
Peptides
Petras R E
Porter E
Proceedings of the National Academy of Sciences of the United States of America
Salzman N H
Schaeffeler E
Schwab M
Science & Technology - Other Topics
Shen B
Stange E F
Wehkamp J
Weichenthal M
-
Text
A resource consisting primarily of words for reading. Examples include books, letters, dissertations, poems, newspapers, articles, archives of mailing lists. Note that facsimiles or images of texts are still of the genre Text.
URL Address
<a href="http://doi.org/10.1093/jac/dkr096" target="_blank" rel="noreferrer noopener">http://doi.org/10.1093/jac/dkr096</a>
Pages
iii19–32
Volume
66 Suppl 3
Dublin Core
The Dublin Core metadata element set is common to all Omeka records, including items, files, and collections. For more information see, http://dublincore.org/documents/dces/.
Title
A name given to the resource
FOCUS 1: a randomized, double-blinded, multicentre, Phase III trial of the efficacy and safety of ceftaroline fosamil versus ceftriaxone in community-acquired pneumonia.
Publisher
An entity responsible for making the resource available
The Journal of antimicrobial chemotherapy
Date
A point or period of time associated with an event in the lifecycle of the resource
2011
2011-04
Subject
The topic of the resource
80 and over; 80 and Over; Aged; Bacteria; Bacteria/isolation & purification; Bacterial – Drug Therapy; Bacterial/*drug therapy; Ceftriaxone – Administration and Dosage; Ceftriaxone – Adverse Effects; Ceftriaxone/administration & dosage/adverse effects; Cephalosporins – Administration and Dosage; Cephalosporins – Adverse Effects; Cephalosporins/*administration & dosage/*adverse effects; Community-Acquired Infections – Drug Therapy; Community-Acquired Infections/*drug therapy; Double-Blind Method; Double-Blind Studies; Female; Human; Humans; Infusions; Intravenous; Male; Middle Age; Middle Aged; Pneumonia; Randomized Controlled Trials; Treatment Outcome; Treatment Outcomes
Creator
An entity primarily responsible for making the resource
File Thomas M Jr; Low Donald E; Eckburg Paul B; Talbot George H; Friedland H David; Lee Jon; Llorens Lily; Critchley Ian A; Thye Dirk A
Description
An account of the resource
OBJECTIVES: Ceftaroline, the active form of the prodrug ceftaroline fosamil, is a novel cephalosporin with bactericidal activity against important pathogens associated with community-acquired pneumonia (CAP), including Streptococcus pneumoniae and common Gram-negative pathogens. FOCUS 1 is a randomized, double-blinded, Phase III study that was conducted to evaluate the efficacy and safety of ceftaroline fosamil in treating patients with CAP. The primary objective was to determine non-inferiority [lower limit of 95% confidence interval (CI) \textgreater/= -10%] in clinical cure rates achieved with ceftaroline fosamil compared with those achieved with ceftriaxone in the clinically evaluable (CE) and modified intent-to-treat efficacy (MITTE) populations. METHODS: Patients hospitalized in a non-intensive care unit setting with CAP of Pneumonia Outcomes Research Team (PORT) risk class III or IV requiring intravenous (iv) therapy were randomized (1:1) to receive 600 mg of ceftaroline fosamil iv every 12 h or 1 g of ceftriaxone iv every 24 h. Patients also received two 500 mg doses of oral clarithromycin every 12 h administered on day 1. Clinical cure, microbiological response, adverse events (AEs) and laboratory tests were assessed. FOCUS 1 registration number NCT00621504 (http://clinicaltrials.gov/ct2/show/NCT00621504). RESULTS: Of 613 enrolled patients, 298 received ceftaroline fosamil and 308 received ceftriaxone. Baseline characteristics between treatment groups were comparable. Clinical cure rates were as follows: CE population, 86.6% (194/224) for ceftaroline fosamil and 78.2% (183/234) for ceftriaxone [difference (95% CI), 8.4% (1.4, 15.4)]; and MITTE population, 83.8% (244/291) for ceftaroline fosamil and 77.7% (233/300) for ceftriaxone [difference (95% CI), 6.2% (-0.2, 12.6)]. Clinical cure rates for CAP caused by S. pneumoniae in the microbiological MITTE population were 88.9% (24/27) and 66.7% (20/30) for ceftaroline fosamil and ceftriaxone, respectively. Both agents were well tolerated, with similar rates of AEs, serious AEs, deaths and discontinuations because of an AE. The most common AEs for ceftaroline fosamil-treated patients were diarrhoea, headache, insomnia and nausea, and the most common AEs for ceftriaxone-treated patients were hypokalaemia, hypertension, nausea and diarrhoea. CONCLUSIONS: Ceftaroline fosamil demonstrated high clinical cure and microbiological response rates in hospitalized patients with CAP of PORT risk class III or IV. Ceftaroline fosamil was well tolerated, with a safety profile similar to that of ceftriaxone and consistent with the cephalosporin class. In this study, ceftaroline fosamil was an effective and well-tolerated treatment option for CAP.
Identifier
An unambiguous reference to the resource within a given context
<a href="http://doi.org/10.1093/jac/dkr096" target="_blank" rel="noreferrer noopener">10.1093/jac/dkr096</a>
Rights
Information about rights held in and over the resource
Article information provided for research and reference use only. All rights are retained by the journal listed under publisher and/or the creator(s).
2011
80 and over
Aged
Bacteria
Bacteria/isolation & purification
Bacterial – Drug Therapy
Bacterial/*drug therapy
Ceftriaxone – Administration and Dosage
Ceftriaxone – Adverse Effects
Ceftriaxone/administration & dosage/adverse effects
Cephalosporins – Administration and Dosage
Cephalosporins – Adverse Effects
Cephalosporins/*administration & dosage/*adverse effects
Community-Acquired Infections – Drug Therapy
Community-Acquired Infections/*drug therapy
Critchley Ian A
Department of Internal Medicine
Double-Blind Method
Double-Blind Studies
Eckburg Paul B
Female
File Thomas M Jr
Friedland H David
Human
Humans
Infusions
Intravenous
Lee Jon
Llorens Lily
Low Donald E
Male
Middle Age
Middle Aged
NEOMED College of Medicine
Pneumonia
RANDOMIZED controlled trials
Talbot George H
The Journal of antimicrobial chemotherapy
Thye Dirk A
Treatment Outcome
Treatment Outcomes
-
Text
A resource consisting primarily of words for reading. Examples include books, letters, dissertations, poems, newspapers, articles, archives of mailing lists. Note that facsimiles or images of texts are still of the genre Text.
URL Address
<a href="http://doi.org/10.1016/j.mayocp.2014.06.010" target="_blank" rel="noreferrer noopener">http://doi.org/10.1016/j.mayocp.2014.06.010</a>
Pages
1318–1318
Issue
9
Volume
89
Dublin Core
The Dublin Core metadata element set is common to all Omeka records, including items, files, and collections. For more information see, http://dublincore.org/documents/dces/.
Title
A name given to the resource
A "solution" for infectious stethoscopes?
Publisher
An entity responsible for making the resource available
Mayo Clinic proceedings
Date
A point or period of time associated with an event in the lifecycle of the resource
2014
2014-09
Subject
The topic of the resource
*Equipment Contamination; *Physical Examination; Aerobic; Aerobic/*isolation & purification; Bacteria; Cross Infection – Transmission; Cross Infection/*transmission; Equipment Contamination; Female; Hand – Microbiology; Hand/*microbiology; Humans; Male; Methicillin-Resistant Staphylococcus Aureus; Methicillin-Resistant Staphylococcus aureus/*isolation & purification; Physical Examination; Stethoscopes; Stethoscopes/*microbiology
Creator
An entity primarily responsible for making the resource
Lecat Paul
Identifier
An unambiguous reference to the resource within a given context
<a href="http://doi.org/10.1016/j.mayocp.2014.06.010" target="_blank" rel="noreferrer noopener">10.1016/j.mayocp.2014.06.010</a>
Rights
Information about rights held in and over the resource
Article information provided for research and reference use only. All rights are retained by the journal listed under publisher and/or the creator(s).
*Equipment Contamination
*Physical Examination
2014
Aerobic
Aerobic/*isolation & purification
Bacteria
Cross Infection – Transmission
Cross Infection/*transmission
Department of Family & Community Medicine
Department of Internal Medicine
Equipment Contamination
Female
Hand – Microbiology
Hand/*microbiology
Humans
Lecat Paul
Male
Mayo Clinic proceedings
Methicillin-Resistant Staphylococcus aureus
Methicillin-Resistant Staphylococcus aureus/*isolation & purification
NEOMED College of Medicine
Physical Examination
Stethoscopes
Stethoscopes/*microbiology